First-line Therapy for metastatic hormone-sensitive Prostate Cancer   (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab   (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus   Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive   Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

Title:: First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO
Document type:: Editorial Material
Author(s):: Rexer, H.; Retz, M.; Hammerer, P.
Journal title abbreviation:: Urologe A
Year:: 2021
Journal volume:: 60
Journal issue:: 7
Pages contribution:: 987-988
Fulltext / DOI:: doi:10.1007/s00120-021-01570-0
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/34255120
Print-ISSN:: 0340-2592
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: